<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705857</url>
  </required_header>
  <id_info>
    <org_study_id>Histograft-NONUNION-1.0</org_study_id>
    <nct_id>NCT04705857</nct_id>
  </id_info>
  <brief_title>Comparative Study of Gene-activated Bone Substitute and Autobone in Treatment of Long Bone Nonunions</brief_title>
  <official_title>Comparative Study of Gene-activated Bone Substitute Based on Octacalcium Phosphate and Plasmid DNA Encoding VEGFA Gene Mixed With Autobone and Bone Autograft From Iliac Crest in Treatment of Long Bone Nonunions With Bone Loss: an Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Histograft Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>S. M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Histograft Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to compare the effectiveness of &quot;Histograft&quot; bone substitute&#xD;
      (gene-activated bone substitute based on octacalcium phosphate and plasmid DNA encoding VEGFA&#xD;
      gene) mixed with shredded autobone and pure shredded auto bone harvested from iliac crest in&#xD;
      treatment of patients with long bone nonunions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label randomized controlled clinical trial, two cohorts. Patients who met the&#xD;
      inclusion criteria are planned to be enrolled into the trial. Upon enrollment, all patients&#xD;
      will undergo screening, a set of clinical examination, instrumental investigations and&#xD;
      laboratory tests, including CT of the affected bone with the assessment of nonunion.&#xD;
&#xD;
      All patients enrolled in the study will be subjected to bone reconstructive surgery with&#xD;
      nonunion excision and bone grafting with either investigational bone substitute mixed with&#xD;
      shredded autobone (in a ratio of 50/50) harvested during the surgery or pure shredded&#xD;
      autobone from iliac crest.&#xD;
&#xD;
      The clinical study results will be evaluated at the time points of 1, 15, 45, 90, 180 days&#xD;
      with clinical examination, instrumental investigations and laboratory tests. Control CT will&#xD;
      be carried out for the primary outcome measure at 90, 180, 360 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone consolidation</measure>
    <time_frame>12 months</time_frame>
    <description>Radiographic assessment of bone healing using REBORNE scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the Adverse Events and Serious Adverse Events frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to use the operated limb</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical assessment using DASH scale (for upper limb) or LEFS scale (for lower limb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain level</measure>
    <time_frame>12 months</time_frame>
    <description>Level of pain measured using Numeric Rating Scale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Union Fracture</condition>
  <condition>Non-Union of Ankle Joint Without Infection</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <description>bone reconstructive surgery with the use of &quot;Histograft&quot; bone substitute (gene-activated matrix based on octacalcium phosphate and plasmid DNA encoding VEGFA gene) mixed with shredded autobone (in a ratio of 50/50) harvested during the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>bone reconstructive surgery with the use of shredded bone autograft harvested from iliac crest</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>&quot;Histograft&quot;, a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene</intervention_name>
    <description>gene-activated bone substitute in granular form, concentration of the plasmid DNA is 100 Î¼g per 1.0 g of the OCP scaffold</description>
    <arm_group_label>test group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients aged 18-70 with non-unions of long bones&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  traumatic isolated closed or open Gustilo I and II, IIIA and IIIB humerus, tibial or&#xD;
             femur diaphyseal or metaphysodiaphyseal fracture with a status of atrophic,&#xD;
             oligotrophic or normotrophic non-union;&#xD;
&#xD;
          -  signed voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypertrophic non-union;&#xD;
&#xD;
          -  disability or unwillingness to give a voluntary informed consent or follow&#xD;
             requirements of the clinical trial;&#xD;
&#xD;
          -  segmental bone loss requiring specific therapy (bone transport, vascularized graft,&#xD;
             large structural allograft, megaprosthesis, etc);&#xD;
&#xD;
          -  other fractures causing interference with weight bearing;&#xD;
&#xD;
          -  visceral injuries or diseases interfering with callus formation (severe&#xD;
             cranioencephalic trauma, etc.);&#xD;
&#xD;
          -  unrecovered vascular or neural injury;&#xD;
&#xD;
          -  infection of any location and aetiology;&#xD;
&#xD;
          -  pregnancy, breast feeding women and women who are of childbearing age and not&#xD;
             practicing adequate birth control;&#xD;
&#xD;
          -  malignant tumour (past history or concurrent disease);&#xD;
&#xD;
          -  history of bone harvesting on iliac crest contraindicating new iliac crest bone graft&#xD;
             harvesting or bone marrow collection;&#xD;
&#xD;
          -  conditions limiting study compliance (e.g., dementia, psycho-neurological diseases,&#xD;
             drug addiction, and alcoholism);&#xD;
&#xD;
          -  medication affecting bone turnover (oral bisphosphonates, PTH, sodium fluoride,&#xD;
             strontium ranelate, calcitonin, testosterone, systemic cortico- or anabolic steroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>S.M. Kirov Military Medical Academy, Department of Traumatology and Orthopaedics</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nonunion</keyword>
  <keyword>gene-activated matrix</keyword>
  <keyword>bone grafting</keyword>
  <keyword>bone substitute</keyword>
  <keyword>VEGF</keyword>
  <keyword>octacalcium phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD could be shared through official depositories located on the clinical base official web site</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

